The global market for Lidexamfetamine Capsules was valued at US$ 1705 million in the year 2024 and is projected to reach a revised size of US$ 2921 million by 2031, growing at a CAGR of 7.9% during the forecast period.

Lidexamfetamine Capsules Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Lidexamfetamine Capsules competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Lisdexamfetamine capsules are an oral solid dosage form containing lisdexamfetamine as the active pharmaceutical ingredient, classified as a central nervous system stimulant. Administered orally, the formulation is metabolized in the body into dextroamphetamine and is primarily indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults, as well as moderate to severe binge eating disorder in adults. The capsule form offers advantages such as stable onset of action, long duration of effect, accurate dosing, and improved patient adherence, making it one of the most widely used clinical formulations. The global sales of Lidexamfetamine Capsules in 2024 amounted to 3.751 million boxes, with an average price of $454.5 per box. The average gross margin for companies was 42.5%, and the annual production capacity per production line was 500,000 boxes.

Regional market landscape

The global market shows clear regional concentration with North America holding 45.2% of total volume, Europe 28.7%, Asia-Pacific 18.3%, Latin America 5.1%, and Middle East & Africa 2.7%; by formulation capsules represent 62.0% of global share, tablets 30.5% and oral solutions 7.5%, while distribution channels are split with hospitals and clinics accounting for 41.3% of demand, retail pharmacies 48.6% and other channels 10.1%, and these fixed regional and channel weights materially influence supply-chain planning, inventory strategy and market entry prioritization.

Key manufacturers and industry competition

The production and supply landscape for lisdexamfetamine is defined by competition between the originator and multiple generic manufacturers: Takeda remains the principal originator with substantial global rights, while generic producers have secured approvals and rapidly scaled capacity across markets; upstream, key chemical raw materials and API intermediates are typically supplied by large chemical firms and CDMOs (for example BASF, Lonza, Evonik and similar suppliers) together with packaging and capsule shell vendors, and downstream distribution is handled by hospitals, wholesalers and retail pharmacy networks, so due diligence must examine originator and generic capacity expansion plans, API sourcing and alternate supply channels, and downstream concentration to assess pricing elasticity and shortage risk.

Technology trends and innovation direction

Current technical trends emphasize improving formulation stability and content uniformity, refining bioequivalence and extended-release evaluation methods, and integrating tighter quality control and digital traceability into manufacturing; generics and CDMOs are reducing costs and improving consistency via process scale-up, continuous flow synthesis and PAT (process analytical technology), while small innovations in excipient selection and patient-friendly oral formulations aim to support adherence, and the integration of bioequivalence data with real-world evidence is increasingly important for approvals and market positioning.

Policy and industry drivers

Regulatory controls and narcotics scheduling are principal drivers shaping lisdexamfetamine’s market, as abuse-prevention measures, national production quotas, generic approval frameworks, pricing reforms and reimbursement decisions directly affect market access and price dynamics; conversely, emergency quota adjustments, incentives for domestic manufacturing and subsidies for local CDMO investment can reshape upstream supply and competitive dynamics.

Outlook

Over the coming years, as multiple generics scale and regulatory approvals broaden, the market is likely to see increased price pressure and diversified supply sources, though episodic regional shortages may persist due to upstream raw-material volatility or regulatory adjustments; for investors and acquirers, focus will shift from standalone financial performance toward robustness of API supply, redundancy in key packaging suppliers, stability of downstream distribution, and durable quality and compliance systems, with firms demonstrating strength across these dimensions positioned to gain competitive advantage.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Lidexamfetamine Capsules, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lidexamfetamine Capsules.

The Lidexamfetamine Capsules market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Lidexamfetamine Capsules market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Lidexamfetamine Capsules manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Lidexamfetamine Capsules Market Report

Report Metric	Details
Report Name	Lidexamfetamine Capsules Market
Accounted market size in year	US$ 1705 million
Forecasted market size in 2031	US$ 2921 million
CAGR	7.9%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	10 mg 20 mg 30 mg 40 mg 50 mg 60 mg 70 mg
Segment by Application	Hospital and Clinic Retail Pharmacies Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Takeda Pharmaceutical, Shionogi, Aristo Pharma GmbH, Sichuan Credit Pharmaceutical, Huahai Pharmaceutical, Hikma Pharmaceuticals, Amneal Pharmaceuticals, Sun Pharmaceutical Industries, Teva Pharmaceutical, Mylan
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Lidexamfetamine Capsules manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Lidexamfetamine Capsules in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Lidexamfetamine Capsules Market growing?

Ans: The Lidexamfetamine Capsules Market witnessing a CAGR of 7.9% during the forecast period 2025-2031.

What is the Lidexamfetamine Capsules Market size in 2031?

Ans: The Lidexamfetamine Capsules Market size in 2031 will be US$ 2921 million.

Who are the main players in the Lidexamfetamine Capsules Market report?

Ans: The main players in the Lidexamfetamine Capsules Market are Takeda Pharmaceutical, Shionogi, Aristo Pharma GmbH, Sichuan Credit Pharmaceutical, Huahai Pharmaceutical, Hikma Pharmaceuticals, Amneal Pharmaceuticals, Sun Pharmaceutical Industries, Teva Pharmaceutical, Mylan

What are the Application segmentation covered in the Lidexamfetamine Capsules Market report?

Ans: The Applications covered in the Lidexamfetamine Capsules Market report are Hospital and Clinic, Retail Pharmacies, Other

What are the Type segmentation covered in the Lidexamfetamine Capsules Market report?

Ans: The Types covered in the Lidexamfetamine Capsules Market report are 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg

1 Lidexamfetamine Capsules Market Overview

1.1 Product Definition

1.2 Lidexamfetamine Capsules by Type

1.2.1 Global Lidexamfetamine Capsules Market Value Comparison by Type (2024 VS 2031)

1.2.2 10 mg

1.2.3 20 mg

1.2.4 30 mg

1.2.5 40 mg

1.2.6 50 mg

1.2.7 60 mg

1.2.8 70 mg

1.3 Lidexamfetamine Capsules by Application

1.3.1 Global Lidexamfetamine Capsules Market Value by Application (2024 VS 2031)

1.3.2 Hospital and Clinic

1.3.3 Retail Pharmacies

1.3.4 Other

1.4 Global Lidexamfetamine Capsules Market Size Estimates and Forecasts

1.4.1 Global Lidexamfetamine Capsules Revenue 2020-2031

1.4.2 Global Lidexamfetamine Capsules Sales 2020-2031

1.4.3 Global Lidexamfetamine Capsules Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Lidexamfetamine Capsules Market Competition by Manufacturers

2.1 Global Lidexamfetamine Capsules Sales Market Share by Manufacturers (2020-2025)

2.2 Global Lidexamfetamine Capsules Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Lidexamfetamine Capsules Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Lidexamfetamine Capsules, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Lidexamfetamine Capsules, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Lidexamfetamine Capsules, Product Type & Application

2.7 Global Key Manufacturers of Lidexamfetamine Capsules, Date of Enter into This Industry

2.8 Global Lidexamfetamine Capsules Market Competitive Situation and Trends

2.8.1 Global Lidexamfetamine Capsules Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Lidexamfetamine Capsules Players Market Share by Revenue

2.8.3 Global Lidexamfetamine Capsules Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Lidexamfetamine Capsules Market Scenario by Region

3.1 Global Lidexamfetamine Capsules Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Lidexamfetamine Capsules Sales by Region: 2020-2031

3.2.1 Global Lidexamfetamine Capsules Sales by Region: 2020-2025

3.2.2 Global Lidexamfetamine Capsules Sales by Region: 2026-2031

3.3 Global Lidexamfetamine Capsules Revenue by Region: 2020-2031

3.3.1 Global Lidexamfetamine Capsules Revenue by Region: 2020-2025

3.3.2 Global Lidexamfetamine Capsules Revenue by Region: 2026-2031

3.4 North America Lidexamfetamine Capsules Market Facts & Figures by Country

3.4.1 North America Lidexamfetamine Capsules Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Lidexamfetamine Capsules Sales by Country (2020-2031)

3.4.3 North America Lidexamfetamine Capsules Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Lidexamfetamine Capsules Market Facts & Figures by Country

3.5.1 Europe Lidexamfetamine Capsules Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Lidexamfetamine Capsules Sales by Country (2020-2031)

3.5.3 Europe Lidexamfetamine Capsules Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Lidexamfetamine Capsules Market Facts & Figures by Region

3.6.1 Asia Pacific Lidexamfetamine Capsules Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Lidexamfetamine Capsules Sales by Region (2020-2031)

3.6.3 Asia Pacific Lidexamfetamine Capsules Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Lidexamfetamine Capsules Market Facts & Figures by Country

3.7.1 Latin America Lidexamfetamine Capsules Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Lidexamfetamine Capsules Sales by Country (2020-2031)

3.7.3 Latin America Lidexamfetamine Capsules Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Lidexamfetamine Capsules Market Facts & Figures by Country

3.8.1 Middle East and Africa Lidexamfetamine Capsules Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Lidexamfetamine Capsules Sales by Country (2020-2031)

3.8.3 Middle East and Africa Lidexamfetamine Capsules Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Lidexamfetamine Capsules Sales by Type (2020-2031)

4.1.1 Global Lidexamfetamine Capsules Sales by Type (2020-2025)

4.1.2 Global Lidexamfetamine Capsules Sales by Type (2026-2031)

4.1.3 Global Lidexamfetamine Capsules Sales Market Share by Type (2020-2031)

4.2 Global Lidexamfetamine Capsules Revenue by Type (2020-2031)

4.2.1 Global Lidexamfetamine Capsules Revenue by Type (2020-2025)

4.2.2 Global Lidexamfetamine Capsules Revenue by Type (2026-2031)

4.2.3 Global Lidexamfetamine Capsules Revenue Market Share by Type (2020-2031)

4.3 Global Lidexamfetamine Capsules Price by Type (2020-2031)

5 Segment by Application

5.1 Global Lidexamfetamine Capsules Sales by Application (2020-2031)

5.1.1 Global Lidexamfetamine Capsules Sales by Application (2020-2025)

5.1.2 Global Lidexamfetamine Capsules Sales by Application (2026-2031)

5.1.3 Global Lidexamfetamine Capsules Sales Market Share by Application (2020-2031)

5.2 Global Lidexamfetamine Capsules Revenue by Application (2020-2031)

5.2.1 Global Lidexamfetamine Capsules Revenue by Application (2020-2025)

5.2.2 Global Lidexamfetamine Capsules Revenue by Application (2026-2031)

5.2.3 Global Lidexamfetamine Capsules Revenue Market Share by Application (2020-2031)

5.3 Global Lidexamfetamine Capsules Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Takeda Pharmaceutical

6.1.1 Takeda Pharmaceutical Company Information

6.1.2 Takeda Pharmaceutical Description and Business Overview

6.1.3 Takeda Pharmaceutical Lidexamfetamine Capsules Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Takeda Pharmaceutical Lidexamfetamine Capsules Product Portfolio

6.1.5 Takeda Pharmaceutical Recent Developments/Updates

6.2 Shionogi

6.2.1 Shionogi Company Information

6.2.2 Shionogi Description and Business Overview

6.2.3 Shionogi Lidexamfetamine Capsules Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Shionogi Lidexamfetamine Capsules Product Portfolio

6.2.5 Shionogi Recent Developments/Updates

6.3 Aristo Pharma GmbH

6.3.1 Aristo Pharma GmbH Company Information

6.3.2 Aristo Pharma GmbH Description and Business Overview

6.3.3 Aristo Pharma GmbH Lidexamfetamine Capsules Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Aristo Pharma GmbH Lidexamfetamine Capsules Product Portfolio

6.3.5 Aristo Pharma GmbH Recent Developments/Updates

6.4 Sichuan Credit Pharmaceutical

6.4.1 Sichuan Credit Pharmaceutical Company Information

6.4.2 Sichuan Credit Pharmaceutical Description and Business Overview

6.4.3 Sichuan Credit Pharmaceutical Lidexamfetamine Capsules Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Sichuan Credit Pharmaceutical Lidexamfetamine Capsules Product Portfolio

6.4.5 Sichuan Credit Pharmaceutical Recent Developments/Updates

6.5 Huahai Pharmaceutical

6.5.1 Huahai Pharmaceutical Company Information

6.5.2 Huahai Pharmaceutical Description and Business Overview

6.5.3 Huahai Pharmaceutical Lidexamfetamine Capsules Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Huahai Pharmaceutical Lidexamfetamine Capsules Product Portfolio

6.5.5 Huahai Pharmaceutical Recent Developments/Updates

6.6 Hikma Pharmaceuticals

6.6.1 Hikma Pharmaceuticals Company Information

6.6.2 Hikma Pharmaceuticals Description and Business Overview

6.6.3 Hikma Pharmaceuticals Lidexamfetamine Capsules Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Hikma Pharmaceuticals Lidexamfetamine Capsules Product Portfolio

6.6.5 Hikma Pharmaceuticals Recent Developments/Updates

6.7 Amneal Pharmaceuticals

6.7.1 Amneal Pharmaceuticals Company Information

6.7.2 Amneal Pharmaceuticals Description and Business Overview

6.7.3 Amneal Pharmaceuticals Lidexamfetamine Capsules Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Amneal Pharmaceuticals Lidexamfetamine Capsules Product Portfolio

6.7.5 Amneal Pharmaceuticals Recent Developments/Updates

6.8 Sun Pharmaceutical Industries

6.8.1 Sun Pharmaceutical Industries Company Information

6.8.2 Sun Pharmaceutical Industries Description and Business Overview

6.8.3 Sun Pharmaceutical Industries Lidexamfetamine Capsules Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Sun Pharmaceutical Industries Lidexamfetamine Capsules Product Portfolio

6.8.5 Sun Pharmaceutical Industries Recent Developments/Updates

6.9 Teva Pharmaceutical

6.9.1 Teva Pharmaceutical Company Information

6.9.2 Teva Pharmaceutical Description and Business Overview

6.9.3 Teva Pharmaceutical Lidexamfetamine Capsules Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Teva Pharmaceutical Lidexamfetamine Capsules Product Portfolio

6.9.5 Teva Pharmaceutical Recent Developments/Updates

6.10 Mylan

6.10.1 Mylan Company Information

6.10.2 Mylan Description and Business Overview

6.10.3 Mylan Lidexamfetamine Capsules Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Mylan Lidexamfetamine Capsules Product Portfolio

6.10.5 Mylan Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Lidexamfetamine Capsules Industry Chain Analysis

7.2 Lidexamfetamine Capsules Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Lidexamfetamine Capsules Production Mode & Process Analysis

7.4 Lidexamfetamine Capsules Sales and Marketing

7.4.1 Lidexamfetamine Capsules Sales Channels

7.4.2 Lidexamfetamine Capsules Distributors

7.5 Lidexamfetamine Capsules Customer Analysis

8 Lidexamfetamine Capsules Market Dynamics

8.1 Lidexamfetamine Capsules Industry Trends

8.2 Lidexamfetamine Capsules Market Drivers

8.3 Lidexamfetamine Capsules Market Challenges

8.4 Lidexamfetamine Capsules Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Takeda Pharmaceutical

Shionogi

Aristo Pharma GmbH

Sichuan Credit Pharmaceutical

Huahai Pharmaceutical

Hikma Pharmaceuticals

Amneal Pharmaceuticals

Sun Pharmaceutical Industries

Teva Pharmaceutical

Mylan NV

List of Tables

Table 1. Global Lidexamfetamine Capsules Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Lidexamfetamine Capsules Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Lidexamfetamine Capsules Market Competitive Situation by Manufacturers in 2024

Table 4. Global Lidexamfetamine Capsules Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Lidexamfetamine Capsules Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Lidexamfetamine Capsules Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Lidexamfetamine Capsules Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Lidexamfetamine Capsules Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Lidexamfetamine Capsules, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Lidexamfetamine Capsules, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Lidexamfetamine Capsules, Product Type & Application

Table 12. Global Key Manufacturers of Lidexamfetamine Capsules, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Lidexamfetamine Capsules by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lidexamfetamine Capsules as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Lidexamfetamine Capsules Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Lidexamfetamine Capsules Sales by Region (2020-2025) & (K Units)

Table 18. Global Lidexamfetamine Capsules Sales Market Share by Region (2020-2025)

Table 19. Global Lidexamfetamine Capsules Sales by Region (2026-2031) & (K Units)

Table 20. Global Lidexamfetamine Capsules Sales Market Share by Region (2026-2031)

Table 21. Global Lidexamfetamine Capsules Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Lidexamfetamine Capsules Revenue Market Share by Region (2020-2025)

Table 23. Global Lidexamfetamine Capsules Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Lidexamfetamine Capsules Revenue Market Share by Region (2026-2031)

Table 25. North America Lidexamfetamine Capsules Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Lidexamfetamine Capsules Sales by Country (2020-2025) & (K Units)

Table 27. North America Lidexamfetamine Capsules Sales by Country (2026-2031) & (K Units)

Table 28. North America Lidexamfetamine Capsules Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Lidexamfetamine Capsules Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Lidexamfetamine Capsules Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Lidexamfetamine Capsules Sales by Country (2020-2025) & (K Units)

Table 32. Europe Lidexamfetamine Capsules Sales by Country (2026-2031) & (K Units)

Table 33. Europe Lidexamfetamine Capsules Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Lidexamfetamine Capsules Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Lidexamfetamine Capsules Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Lidexamfetamine Capsules Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Lidexamfetamine Capsules Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Lidexamfetamine Capsules Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Lidexamfetamine Capsules Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Lidexamfetamine Capsules Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Lidexamfetamine Capsules Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Lidexamfetamine Capsules Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Lidexamfetamine Capsules Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Lidexamfetamine Capsules Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Lidexamfetamine Capsules Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Lidexamfetamine Capsules Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Lidexamfetamine Capsules Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Lidexamfetamine Capsules Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Lidexamfetamine Capsules Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Lidexamfetamine Capsules Sales (K Units) by Type (2020-2025)

Table 51. Global Lidexamfetamine Capsules Sales (K Units) by Type (2026-2031)

Table 52. Global Lidexamfetamine Capsules Sales Market Share by Type (2020-2025)

Table 53. Global Lidexamfetamine Capsules Sales Market Share by Type (2026-2031)

Table 54. Global Lidexamfetamine Capsules Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Lidexamfetamine Capsules Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Lidexamfetamine Capsules Revenue Market Share by Type (2020-2025)

Table 57. Global Lidexamfetamine Capsules Revenue Market Share by Type (2026-2031)

Table 58. Global Lidexamfetamine Capsules Price (US$/Unit) by Type (2020-2025)

Table 59. Global Lidexamfetamine Capsules Price (US$/Unit) by Type (2026-2031)

Table 60. Global Lidexamfetamine Capsules Sales (K Units) by Application (2020-2025)

Table 61. Global Lidexamfetamine Capsules Sales (K Units) by Application (2026-2031)

Table 62. Global Lidexamfetamine Capsules Sales Market Share by Application (2020-2025)

Table 63. Global Lidexamfetamine Capsules Sales Market Share by Application (2026-2031)

Table 64. Global Lidexamfetamine Capsules Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Lidexamfetamine Capsules Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Lidexamfetamine Capsules Revenue Market Share by Application (2020-2025)

Table 67. Global Lidexamfetamine Capsules Revenue Market Share by Application (2026-2031)

Table 68. Global Lidexamfetamine Capsules Price (US$/Unit) by Application (2020-2025)

Table 69. Global Lidexamfetamine Capsules Price (US$/Unit) by Application (2026-2031)

Table 70. Takeda Pharmaceutical Company Information

Table 71. Takeda Pharmaceutical Description and Business Overview

Table 72. Takeda Pharmaceutical Lidexamfetamine Capsules Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Takeda Pharmaceutical Lidexamfetamine Capsules Product

Table 74. Takeda Pharmaceutical Recent Developments/Updates

Table 75. Shionogi Company Information

Table 76. Shionogi Description and Business Overview

Table 77. Shionogi Lidexamfetamine Capsules Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Shionogi Lidexamfetamine Capsules Product

Table 79. Shionogi Recent Developments/Updates

Table 80. Aristo Pharma GmbH Company Information

Table 81. Aristo Pharma GmbH Description and Business Overview

Table 82. Aristo Pharma GmbH Lidexamfetamine Capsules Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Aristo Pharma GmbH Lidexamfetamine Capsules Product

Table 84. Aristo Pharma GmbH Recent Developments/Updates

Table 85. Sichuan Credit Pharmaceutical Company Information

Table 86. Sichuan Credit Pharmaceutical Description and Business Overview

Table 87. Sichuan Credit Pharmaceutical Lidexamfetamine Capsules Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Sichuan Credit Pharmaceutical Lidexamfetamine Capsules Product

Table 89. Sichuan Credit Pharmaceutical Recent Developments/Updates

Table 90. Huahai Pharmaceutical Company Information

Table 91. Huahai Pharmaceutical Description and Business Overview

Table 92. Huahai Pharmaceutical Lidexamfetamine Capsules Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Huahai Pharmaceutical Lidexamfetamine Capsules Product

Table 94. Huahai Pharmaceutical Recent Developments/Updates

Table 95. Hikma Pharmaceuticals Company Information

Table 96. Hikma Pharmaceuticals Description and Business Overview

Table 97. Hikma Pharmaceuticals Lidexamfetamine Capsules Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Hikma Pharmaceuticals Lidexamfetamine Capsules Product

Table 99. Hikma Pharmaceuticals Recent Developments/Updates

Table 100. Amneal Pharmaceuticals Company Information

Table 101. Amneal Pharmaceuticals Description and Business Overview

Table 102. Amneal Pharmaceuticals Lidexamfetamine Capsules Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Amneal Pharmaceuticals Lidexamfetamine Capsules Product

Table 104. Amneal Pharmaceuticals Recent Developments/Updates

Table 105. Sun Pharmaceutical Industries Company Information

Table 106. Sun Pharmaceutical Industries Description and Business Overview

Table 107. Sun Pharmaceutical Industries Lidexamfetamine Capsules Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. Sun Pharmaceutical Industries Lidexamfetamine Capsules Product

Table 109. Sun Pharmaceutical Industries Recent Developments/Updates

Table 110. Teva Pharmaceutical Company Information

Table 111. Teva Pharmaceutical Description and Business Overview

Table 112. Teva Pharmaceutical Lidexamfetamine Capsules Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. Teva Pharmaceutical Lidexamfetamine Capsules Product

Table 114. Teva Pharmaceutical Recent Developments/Updates

Table 115. Mylan Company Information

Table 116. Mylan Description and Business Overview

Table 117. Mylan Lidexamfetamine Capsules Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 118. Mylan Lidexamfetamine Capsules Product

Table 119. Mylan Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Lidexamfetamine Capsules Distributors List

Table 123. Lidexamfetamine Capsules Customers List

Table 124. Lidexamfetamine Capsules Market Trends

Table 125. Lidexamfetamine Capsules Market Drivers

Table 126. Lidexamfetamine Capsules Market Challenges

Table 127. Lidexamfetamine Capsules Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

Table 131. Authors List of This Report

List of Figures

Figure 1. Product Picture of Lidexamfetamine Capsules

Figure 2. Global Lidexamfetamine Capsules Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Lidexamfetamine Capsules Market Share by Type: 2024 & 2031

Figure 4. 10 mg Product Picture

Figure 5. 20 mg Product Picture

Figure 6. 30 mg Product Picture

Figure 7. 40 mg Product Picture

Figure 8. 50 mg Product Picture

Figure 9. 60 mg Product Picture

Figure 10. 70 mg Product Picture

Figure 11. Global Lidexamfetamine Capsules Market Value by Application (2020-2031) & (US$ Million)

Figure 12. Global Lidexamfetamine Capsules Market Share by Application: 2024 & 2031

Figure 13. Hospital and Clinic

Figure 14. Retail Pharmacies

Figure 15. Other

Figure 16. Global Lidexamfetamine Capsules Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Lidexamfetamine Capsules Market Size (2020-2031) & (US$ Million)

Figure 18. Global Lidexamfetamine Capsules Sales (2020-2031) & (K Units)

Figure 19. Global Lidexamfetamine Capsules Average Price (US$/Unit) & (2020-2031)

Figure 20. Lidexamfetamine Capsules Report Years Considered

Figure 21. Lidexamfetamine Capsules Sales Share by Manufacturers in 2024

Figure 22. Global Lidexamfetamine Capsules Revenue Share by Manufacturers in 2024

Figure 23. Global 5 and 10 Largest Lidexamfetamine Capsules Players: Market Share by Revenue in Lidexamfetamine Capsules in 2024

Figure 24. Lidexamfetamine Capsules Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 25. Global Lidexamfetamine Capsules Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 26. North America Lidexamfetamine Capsules Sales Market Share by Country (2020-2031)

Figure 27. North America Lidexamfetamine Capsules Revenue Market Share by Country (2020-2031)

Figure 28. United States Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Canada Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Europe Lidexamfetamine Capsules Sales Market Share by Country (2020-2031)

Figure 31. Europe Lidexamfetamine Capsules Revenue Market Share by Country (2020-2031)

Figure 32. Germany Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. France Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. U.K. Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Italy Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Russia Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Asia Pacific Lidexamfetamine Capsules Sales Market Share by Region (2020-2031)

Figure 38. Asia Pacific Lidexamfetamine Capsules Revenue Market Share by Region (2020-2031)

Figure 39. China Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Japan Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. South Korea Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. India Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Australia Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. China Taiwan Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Southeast Asia Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Latin America Lidexamfetamine Capsules Sales Market Share by Country (2020-2031)

Figure 47. Latin America Lidexamfetamine Capsules Revenue Market Share by Country (2020-2031)

Figure 48. Mexico Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Brazil Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Argentina Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Colombia Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Middle East and Africa Lidexamfetamine Capsules Sales Market Share by Country (2020-2031)

Figure 53. Middle East and Africa Lidexamfetamine Capsules Revenue Market Share by Country (2020-2031)

Figure 54. Turkey Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Saudi Arabia Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. UAE Lidexamfetamine Capsules Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. Global Sales Market Share of Lidexamfetamine Capsules by Type (2020-2031)

Figure 58. Global Revenue Market Share of Lidexamfetamine Capsules by Type (2020-2031)

Figure 59. Global Lidexamfetamine Capsules Price (US$/Unit) by Type (2020-2031)

Figure 60. Global Sales Market Share of Lidexamfetamine Capsules by Application (2020-2031)

Figure 61. Global Revenue Market Share of Lidexamfetamine Capsules by Application (2020-2031)

Figure 62. Global Lidexamfetamine Capsules Price (US$/Unit) by Application (2020-2031)

Figure 63. Lidexamfetamine Capsules Value Chain

Figure 64. Channels of Distribution (Direct Vs Distribution)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Lidexamfetamine Capsules Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-13H20042

Fri Oct 10 00:00:00 UTC 2025

Add to Cart

Global Autism Drug Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9T16706

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global ADHD Planner App Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34C16185

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Autism Digital Therapy Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-2E16662

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions